Full Text
Retinal vein occlusion is considered the second most common retinal vascular disorder after diabetic retinopathy and represents an important cause of visual disability worldwide. The disease develops when venous blood flow within the retinal circulation becomes obstructed, leading to increased intravascular pressure, vascular leakage, hemorrhage, and ischemic damage to retinal tissues. Clinical manifestations often include sudden decrease in visual acuity, distortion of central vision, and structural alterations of the retina detected during ophthalmic examination. For many years the development of retinal vein occlusion was primarily associated with traditional cardiovascular risk factors such as arterial hypertension, diabetes mellitus, hyperlipidemia, and atherosclerotic vascular changes. These systemic conditions contribute to endothelial dysfunction and increased blood viscosity, which facilitate thrombus formation in retinal vessels. Nevertheless, growing evidence indicates that systemic thrombophilic states may also play an important role in the pathogenesis of retinal venous occlusion. Thrombophilia refers to a group of inherited or acquired disorders characterized by increased tendency toward blood clot formation. Genetic mutations affecting coagulation factors, platelet activation pathways, and homocysteine metabolism may significantly increase the risk of vascular thrombosis. In many individuals these abnormalities remain clinically silent until a thrombotic event occurs in a sensitive vascular territory such as the retinal circulation. Because retinal vessels are easily accessible for direct visualization, retinal vein occlusion may serve as an early indicator of systemic thrombotic predisposition. Recognition of this relationship is crucial for preventing recurrent ocular events as well as potentially severe systemic complications including deep vein thrombosis, pulmonary embolism, and cerebrovascular accidents. Retinal vascular disorders represent an important cause of visual impairment in modern ophthalmology, and occlusion of the retinal venous system occupies a prominent position among these conditions. The disease develops when normal blood flow through the retinal veins becomes obstructed, leading to increased venous pressure, vascular leakage, intraretinal hemorrhage, and progressive structural damage to retinal tissues. In many cases patients experience sudden deterioration of visual acuity accompanied by morphological changes detected during fundus examination and imaging studies. Historically, the development of retinal venous obstruction has been primarily attributed to systemic cardiovascular conditions including arterial hypertension, metabolic disturbances related to diabetes mellitus, and lipid metabolism disorders. These factors contribute to endothelial dysfunction and changes in vascular wall integrity that facilitate thrombus formation within retinal vessels. However, recent scientific investigations have expanded the understanding of the pathogenesis of this disorder by emphasizing the role of systemic abnormalities in the coagulation system. Thrombophilia refers to a group of conditions characterized by an increased tendency for pathological blood clot formation due to inherited genetic mutations or acquired hematological disturbances. Individuals affected by such abnormalities may remain clinically asymptomatic for long periods until a thrombotic event occurs in a sensitive vascular territory. Because the retinal circulation is highly susceptible to changes in blood flow dynamics and coagulation balance, retinal vein occlusion may represent one of the earliest manifestations of systemic hypercoagulability. Recognition of this relationship has important clinical implications, as early identification of thrombophilic states may allow prevention of recurrent ocular events and potentially life-threatening systemic complications.
2. Materials and Methods
The present investigation included patients diagnosed with retinal vein occlusion who underwent detailed clinical and laboratory evaluation. All participants received comprehensive ophthalmological assessment including measurement of best corrected visual acuity, slit-lamp examination, intraocular pressure measurement, and dilated fundus examination. Optical coherence tomography was performed to evaluate retinal thickness and detect macular edema. Fluorescein angiography was used in selected cases to determine the extent of retinal ischemia and vascular obstruction. In addition to ophthalmic evaluation, systemic examination was carried out to identify possible cardiovascular and metabolic risk factors. Blood pressure measurement, fasting glucose analysis, and lipid profile assessment were performed for all patients. Special attention was directed toward identifying potential thrombophilic conditions. Blood samples were analyzed for abnormalities in coagulation parameters and genetic markers associated with thrombotic disorders. Molecular testing included screening for mutations affecting coagulation pathways and genes involved in thrombosis regulation. Patients were subsequently evaluated through interdisciplinary consultation involving ophthalmologists, hematologists, and internal medicine specialists in order to establish a comprehensive clinical profile and determine the presence of systemic thrombophilia.
Clinical and laboratory analysis demonstrated that a considerable proportion of patients presenting with retinal vein occlusion exhibited previously undiagnosed abnormalities related to coagulation function. In addition to traditional cardiovascular risk factors, several individuals were found to possess inherited or acquired thrombophilic conditions that increased their susceptibility to vascular occlusion. Genetic analysis revealed the presence of mutations affecting coagulation regulation and homocysteine metabolism in a subset of patients. These findings suggest that retinal venous obstruction may occur as an early manifestation of systemic thrombotic predisposition. Patients identified with thrombophilic abnormalities showed higher incidence of bilateral retinal involvement, recurrent vascular events, and prolonged retinal ischemia compared with individuals without such conditions. In many cases the ocular event served as the first clinical indicator that prompted further investigation and subsequent diagnosis of systemic thrombophilia. The implementation of multidisciplinary evaluation allowed early detection of these disorders and facilitated the initiation of preventive systemic therapy aimed at reducing the risk of additional thrombotic complications. Comprehensive clinical evaluation revealed that many individuals presenting with retinal venous obstruction had previously unrecognized abnormalities related to blood coagulation and vascular regulation. In addition to traditional cardiovascular risk factors, laboratory analysis demonstrated the presence of hypercoagulable states in a considerable proportion of patients. Genetic screening identified variants associated with increased thrombotic activity and impaired regulation of coagulation pathways. These abnormalities were particularly evident in patients who experienced severe retinal ischemia, bilateral involvement, or repeated vascular events during follow-up observation. Structural examination of the retina frequently showed extensive hemorrhagic changes and pronounced macular edema in individuals with underlying thrombophilic predisposition. The identification of coagulation disorders prompted further systemic evaluation, leading to confirmation of hereditary or acquired thrombophilia in several cases. As a result, the ocular vascular event served as the first clinical signal indicating the presence of systemic pathology affecting the hemostatic system.
The results of this investigation support the concept that retinal vein occlusion may function as an important ophthalmic marker of systemic thrombotic disorders. The retinal circulation represents a delicate microvascular network that is particularly sensitive to alterations in blood flow dynamics and coagulation activity. Even minor disturbances in hemostatic balance can lead to occlusion of retinal vessels and subsequent visual impairment. Identification of thrombophilic conditions in patients presenting with retinal vein occlusion highlights the necessity of expanding diagnostic evaluation beyond purely ophthalmic assessment. An interdisciplinary approach involving collaboration between ophthalmologists, hematologists, and genetic specialists allows a more comprehensive understanding of the underlying mechanisms responsible for vascular obstruction. Early detection of thrombophilia is particularly important because many affected individuals remain asymptomatic until a major thrombotic event occurs. Recognition of retinal vein occlusion as a possible sentinel event provides an opportunity for timely systemic intervention and long-term prevention of serious complications affecting other organs. The observations obtained from this investigation emphasize the importance of considering retinal venous obstruction as more than an isolated ophthalmic condition. The retinal vascular network represents a highly sensitive component of the systemic circulatory system, and disturbances in coagulation balance may manifest in this region earlier than in other organs. When thrombophilic abnormalities are present, even minor alterations in blood flow dynamics may trigger vascular blockage and subsequent retinal damage. The identification of hidden coagulation disorders in patients presenting with retinal vein occlusion highlights the necessity of expanding diagnostic evaluation beyond standard ophthalmological assessment. Interdisciplinary cooperation between specialists in ophthalmology, hematology, and clinical genetics allows a more comprehensive investigation of the underlying causes of vascular occlusion. Such collaboration is essential for establishing appropriate therapeutic strategies that address both ocular manifestations and systemic predisposition to thrombosis. Early recognition of thrombophilia provides an opportunity to initiate preventive treatment aimed at reducing the risk of recurrent ocular events and other thrombotic complications affecting vital organs.
Retinal vein occlusion should be considered not only a localized ocular disorder but also a potential clinical indicator of systemic thrombotic predisposition. A significant number of patients presenting with this condition may harbor previously undetected thrombophilic abnormalities that contribute to vascular occlusion. Comprehensive evaluation including genetic and hematological investigation is therefore essential for accurate diagnosis and effective management. Implementation of an interdisciplinary diagnostic strategy enables early identification of systemic risk factors and supports the development of individualized treatment and prevention programs. Such an approach may improve both ophthalmic outcomes and overall patient health by reducing the likelihood of recurrent thrombotic events. Retinal vein occlusion should be regarded as a potential ophthalmic indicator of systemic thrombotic predisposition rather than solely a localized vascular disorder of the eye. A significant number of patients presenting with this condition may harbor previously undetected abnormalities of the coagulation system that increase susceptibility to vascular occlusion. Comprehensive evaluation that includes hematological and genetic investigation is therefore essential for accurate diagnosis and effective management. Implementation of a multidisciplinary diagnostic approach enables early detection of thrombophilic conditions and supports the development of individualized prevention strategies. Such measures may improve visual prognosis while simultaneously reducing the likelihood of serious systemic thrombotic events in affected individuals.
1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic retinopathy.
3. Lewis H. Vitrectomy for complications of diabetic retinopathy.
4. Diabetic Retinopathy Clinical Research Network. Surgical management of proliferative diabetic retinopathy.
5. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy pathophysiology.
6. Schwartz S.G., Flynn H.W. Pars plana vitrectomy for diabetic retinopathy complications.
7. Stewart M.W. Current management of diabetic retinopathy.
8. Kanski J.J., Bowling B. Clinical Ophthalmology: A Systematic Approach.
9. Stefansson E. Oxygenation and diabetic retinal disease.
10. American Academy of Ophthalmology. Retina and Vitreous Clinical Guidelines.
11. https://med1.uz/articles/oftalmologiya/glaukoma